How to buy Pulmonx stock (Pulmonx)

Pulmonx is a medical devices business based in the US. Pulmonx shares (LUNG) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.26 – an increase of 2.12% over the previous week. Pulmonx employs 279 staff and has a trailing 12-month revenue of around $79.3 million.

Our top picks for where to buy Pulmonx Corp stock

Buy Pulmonx stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pulmonx stock price (NASDAQ: LUNG)

Use our graph to track the performance of LUNG stocks over time.

Pulmonx shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$6.26
52-week range	$5.46 - $14.84
50-day moving average more info button	$6.54
200-day moving average more info button	$7.37
Wall St. target price	$11.92
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.47

Is it a good time to buy Pulmonx stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pulmonx price performance over time

Historical closes compared with the close of $6.15 from 2024-12-20

1 week (2024-12-17)	0.33%
1 month (2024-11-22)	-9.43%
3 months (2024-09-24)	-26.35%
6 months (2024-06-24)	0.16%

1 year (2023-12-22)	-51.54%
2 years (2022-12-23)	-21.66%
3 years (2021-12-23)	33.02
5 years (2019-12-20)	N/A

Pulmonx financials

Revenue TTM	$79.3 million
Gross profit TTM	$39.9 million
Return on assets TTM	-20.04%
Return on equity TTM	-51.99%
Profit margin	-72.01%
Book value	$2.38
Market Capitalization more info button	$240.9 million

TTM: trailing 12 months

Pulmonx share dividends

We're not expecting Pulmonx to pay a dividend over the next 12 months.

You may also wish to consider:

• ResMed (RMD.US) (0.92% forward annual dividend yield)

Pulmonx share price volatility

Over the last 12 months, Pulmonx's shares have ranged in value from as little as $5.46 up to $14.835. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pulmonx's is 0.684. This would suggest that Pulmonx's shares are less volatile than average (for this exchange).

To put Pulmonx's beta into context you can compare it against those of similar companies.

• ResMed (RMD.US): 0.687
• Boston Scientific (BSX.US): 0.797
• Pulmatrix (PULM.US): 0.988

Pulmonx overview

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. .

Frequently asked questions

What percentage of Pulmonx is owned by insiders or institutions?
Currently 4.984% of Pulmonx shares are held by insiders and 94.863% by institutions. How many people work for Pulmonx?
Latest data suggests 279 work at Pulmonx. When does the fiscal year end for Pulmonx?
Pulmonx's fiscal year ends in December. Where is Pulmonx based?
Pulmonx's address is: 700 Chesapeake Drive, Redwood City, CA, United States, 94063 What is Pulmonx's ISIN number?
Pulmonx's international securities identification number is: US7458481014